Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret complex documents. As a biotechnology issuer focused on RNA-targeted medicines, Ionis uses filings such as Forms 8-K, 10-Q and 10-K to report clinical milestones, regulatory events, financing transactions and operating results.
Recent Form 8-K filings illustrate how Ionis communicates material developments. The company has furnished press releases on pivotal Phase 3 CORE and CORE2 results for olezarsen in severe hypertriglyceridemia, positive pivotal data for zilganersen in Alexander disease, and FDA approval of DAWNZERA (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema. Other 8-Ks describe FDA Breakthrough Therapy designations, European regulatory opinions and key clinical readouts across neurology and cardiometabolic programs.
Ionis also uses current reports to disclose capital markets activity. One 8-K details the issuance of 0.00% Convertible Senior Notes due 2030, including the terms of the indenture, conversion mechanics, redemption provisions, events of default and use of proceeds, such as repurchasing earlier convertible notes and funding general corporate purposes. Additional filings cover quarterly financial results, where the company presents both GAAP and non-GAAP measures, and governance or contractual matters like advisory services agreements.
On this page, Stock Titan connects directly to EDGAR to surface new Ionis filings as they are posted. AI-powered summaries help explain lengthy documents, highlighting items such as clinical trial outcomes, regulatory status updates, financing terms, risk factor changes and other key disclosures. Investors can quickly locate annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other relevant filings, and use the AI analysis to understand how each document may relate to Ionis’ RNA-targeted pipeline, marketed medicines and capital structure.
Ionis Pharmaceuticals executive Holly B. Kordasiewicz, EVP and Chief Development Officer, reported multiple equity transactions. On 01/15/2026, 11,119 shares of common stock were acquired at $0.0 per share through the vesting and release of previously granted restricted stock units. On 01/16/2026, 4,141 shares were sold at a weighted average price of $75.66 per share in an automatic sale to cover tax withholding obligations under the company’s equity incentive plan, leaving 14,718 common shares directly owned.
On the derivative side, restricted stock units were exercised or granted at $0.0 per unit on 01/15/2026. An RSU conversion of 11,119 units reduced the RSU balance to 20,830 units. Additional grants of 13,650 and 11,250 RSUs increased the total RSU holdings to 45,730 units. Each RSU represents the right to receive one share of Ionis common stock or its cash equivalent, vesting in four equal annual installments.
Ionis Pharmaceuticals executive Kyle Jenne reported equity award activity and a small stock sale. On January 15, 2026, Jenne acquired 7,013 shares of common stock at $0.00 through the vesting and release of previously granted restricted stock units. The filing shows he then held 18,212 common shares directly.
On the same date, he received 25,800 performance restricted stock units, representing the maximum that may be earned over a three-year period based on Ionis’s relative total shareholder return, and 9,675 time-based restricted stock units that vest in four equal annual installments. On January 16, 2026, Jenne sold 1,823 shares of common stock at a weighted average price of $75.96, in an automatic sale to cover tax-withholding obligations, leaving him with 16,389 common shares held directly.
Ionis Pharmaceuticals EVP, Finance & CFO Elizabeth L. Hougen reported several equity award transactions and a small share sale. On January 15, 2026, 28,729 Restricted Stock Units (RSUs) vested and were converted into common stock at an exercise price of $0.0, and she received a new grant of 34,360 Performance RSUs and 12,885 RSUs under the company’s 2011 Equity Incentive Plan. The performance units may vest after a three-year period based on relative total shareholder return, with the amount reported representing the maximum that can be earned.
On January 16, 2026, she sold 12,922 shares of common stock at a weighted average price of $75.22 to cover tax withholding obligations related to the RSU vesting. After these transactions, she directly held 126,307 shares of common stock, 120,995 Performance RSUs, and 68,825 RSUs.
Ionis Pharmaceuticals executive Shannon L. Devers, EVP and Chief Human Resources Officer, reported multiple equity transactions in January 2026. On January 15, 2026, 17,377 shares of common stock were acquired upon vesting of restricted stock units at an exercise price of $0.0, and on January 16, 2026, 8,353 shares of common stock were sold in an automatic sale to cover tax withholding at a weighted average price of $75.95.
Devers also received 25,800 Performance Restricted Stock Units, representing the maximum that may be earned based on a three-year performance period, and 9,675 Restricted Stock Units that vest in four equal annual installments. Following these transactions, she directly beneficially owned 26,518 shares of common stock, 47,800 Performance RSUs, and 52,704 RSUs, each RSU representing a contingent right to one share of Ionis common stock or its cash equivalent.
Ionis Pharmaceuticals executive Brian Birchler reported several equity transactions. On January 15, 2026, 20,089 shares of common stock were acquired at $0.0 per share upon vesting and release of restricted stock units, increasing his direct holdings to 68,915 shares. On January 16, 2026, he sold 8,480 shares of common stock at a weighted average price of $75.11 per share in an automatic sale to cover tax withholding, leaving 60,435 common shares directly owned.
Birchler also received equity awards on January 15, 2026, including 25,800 Performance Restricted Stock Units (PRSUs), representing the maximum that may be earned based on three‑year relative total shareholder return, and a grant of 9,675 Restricted Stock Units (RSUs). These PRSUs may vest at the end of the three‑year period, while RSUs generally vest in four equal annual installments, each unit representing a right to one share of Ionis common stock or its cash equivalent.
Ionis Pharmaceuticals executive C. Frank Bennett, EVP and Chief Scientific Officer, reported multiple equity transactions. On January 15, 2026, 21,055 shares of common stock were acquired at $0.0 per share through the vesting and release of restricted stock units, increasing his direct common stock holdings to 103,734 shares. On January 16, 2026, he sold 8,977 shares of common stock at a weighted average price of $75.15 per share in an automatic sale to cover tax withholding obligations, leaving 94,757 shares owned directly.
He was also granted 25,800 Performance Restricted Stock Units (PRSUs), representing the maximum that may be earned based on a three-year relative total shareholder return performance period, and 9,675 Restricted Stock Units (RSUs) that vest in four equal annual installments. Each RSU or PRSU represents a contingent right to receive one share of Ionis common stock or its cash equivalent.
Ionis Pharmaceuticals executive Joseph Baroldi reported equity award activity and related share sales. On 01/15/2026, restricted stock units vested, resulting in the acquisition of 17,037 shares of common stock directly and 2,850 shares indirectly through his spouse at an exercise price of $0.0 per share. Following these transactions, he held 47,338 common shares directly and 5,921 shares indirectly through his spouse.
On 01/16/2026, he reported sales of 6,907 directly held shares at a weighted average price of $75.75 and 1,149 indirectly held shares at $75.78, described as automatic sales to cover tax withholding obligations. Separately, on 01/15/2026 he received a grant of 25,800 performance restricted stock units that may vest after a three‑year performance period, as well as additional restricted stock unit grants for himself and his spouse under the company’s equity incentive plan.
Ionis Pharmaceuticals plans an insider share sale under Rule 144. A holder intends to sell 9,884 shares of Ionis common stock through Morgan Stanley Smith Barney, with an approximate sale date of 01/16/2026 on the NASDAQ. The filing notes that 161,137,930 shares of common stock are outstanding.
The 9,884 shares come from restricted stock units granted on 01/15/2026 under the company’s 2011 Equity Incentive Plan, treated as compensation. Over the prior three months, the same account, using Morgan Stanley Smith Barney as seller, sold 23,463 common shares on 01/02/2026 for gross proceeds of $1,856,324.51. The signer represents they are not aware of any undisclosed material adverse information about Ionis.
Ionis Pharmaceuticals has a notice of proposed sale under Rule 144 for 6,999 shares of its common stock. The shares are expected to be sold on or about 01/16/2026 through broker Morgan Stanley Smith Barney on the NASDAQ market, with an aggregate market value of $559,920. The filing notes that these shares were acquired on 01/15/2026 as restricted stock units granted under the company’s 2011 Equity Incentive Plan and delivered as compensation. The filing also reports that 161,974,393 shares of Ionis common stock were outstanding, providing context for the planned sale size.
Ionis Pharmaceuticals has a planned insider sale disclosed through a Rule 144 notice. The filing covers the potential sale of 8,977 shares of common stock through Morgan Stanley Smith Barney on the NASDAQ, with an aggregate market value of $684,263.90. These shares were acquired on 01/15/2026 as restricted stock units granted under the company’s 2011 Equity Incentive Plan and classified as compensation. The planned sale date is approximately 01/16/2026. The filing also notes that 161,137,930 shares of Ionis common stock were outstanding, providing context for the size of this transaction.